In a 10-year period in the early 2000’s, hospital-based (nosocomial) infections increased by 123%, and this number is increasing as time goes on. The purpose of this experiment was to use hyaluronic acid, silver nanoparticles, and a bacteriophage cocktail to create a hydrogel that promotes wound healing by increasing cell proliferation while simultaneously disrupting biofilm formation and breaking down Staphylococcus aureus and Pseudomonas aeruginosa, which are two strains of bacteria that attribute to nosocomial infections and are increasing in antibiotic resistance.

In this study, Imani et al. investigate whether a new proprietary herbal formulation, HF1, can inhibit expression of immune suppressor protein PD-L1. PD-L1 is a transmembrane protein that can be expressed by cancer cells to assist in their ability to avoid attacks from the immune system. Work from this study demonstrates that HF1 treatment can reduce expression of PD-L1 in cultured cancer cells, implicating HF1 as a potential new cancer therapy.

The major drawback of chemotherapy regimens for treating cancer is that the cancerous cells acquire drug resistance and become impervious to further dose escalation. Keeping in mind the studied success of herbal formulations with regard to alternative treatments for cancer, we hypothesized that the use of a chemotherapeutic drug and proprietary herbal formulation, HF1, would combat this phenomenon when administered with common chemotherapeutic drug 5FU. Results demonstrated a cooperative effect between HF1 and 5FU on the drug resistant cell line, implying that administration of HF1 with 5FU results in cell death as measured by MTT assay.